How a patent dispute with 10x helped decimate NanoString’s stock price
Recent $31 million damages award has dealt a further blow to the company's faltering share value
Recent $31 million damages award has dealt a further blow to the company's faltering share value
IAM Connect: Patent Policy and Litigation delved deeply into Section 101 legislation, reform efforts at the Patent Trial and Appeal Board, and reactions to the European Commission's SEP proposal
We spotlight IP funding programmes in Singapore, Germany, China, and the European Union that incentivise small-to-medium-sized enterprises to globalise their patent portfolios
Hesai Photonics Technology reveals monetary details of settlement, which also involves ongoing royalty payments through 2030
22 January 2021
Despite a turbulent 2020 for pharma transactions, it is possible to discern a few patterns for activity in the market this year
19 January 2021
USPTO report on non-market patent incentives shows how Chinese applicants are being encouraged to obtain more foreign rights
14 January 2021
A year after a major capital infusion and a change of leadership, the firm has notched some notable settlements in the US and laid the groundwork for new assertion campaigns
08 January 2021
Licensing business that shed state sponsorship last year partners with Korean patent powerhouse in latest acquisition
05 January 2021
Patent licensing is as much an art as it is a science, explain some of those featured in the new IAM Strategy 300 Global Leaders guide
22 December 2020
As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies.
22 December 2020
It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver
16 December 2020
A recent report suggests Wall Street is beginning to realise that the rise of intangible assets has thrown a spanner into time-tested valuation models
12 December 2020
In an exclusive interview, Hans Sauer talks of concerns over a shift in federal strategy and argues that government research funding should not be seen as a commercial investment
03 December 2020
Unlock unlimited access to all IAM content